Fundz

Rare Cyte, Inc. reported raising $24 Million in an initial SEC Form D filing, from an offering of $24 Million

PRIVATESep 10, 2021

Amount Raised

$24 Million

$24 Million sold, per SEC Form D (first sale Sep 10, 2021)

Round Type

Venture

SeattleOther

Quick answer

RareCyte, Inc. raised $24 Million in a funding round, dated September 10, 2021. RareCyte, Inc. is based in Seattle, Washington, United States.

How much did RareCyte, Inc. raise?
RareCyte, Inc. raised $24 Million in a funding round on September 10, 2021.
What does RareCyte, Inc. do?
Leaders across Research, Translational Medicine and the Clinic rely on RareCyte as a one-stop resource for Spatial Biology and Liquid Biopsy solutions.
Where is RareCyte, Inc. based and how big is it?
RareCyte, Inc. is based in Seattle, Washington, United States. Fundz records about 62 employees.
Who are the decision-makers at RareCyte, Inc?
Fundz holds 1 contact at RareCyte, Inc., including the Director. Names and contact details are shown to Fundz members.

Source: Fundz verified event record.

Who to call at RareCyte, Inc., and when

A new round usually means RareCyte, Inc. is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day RareCyte, Inc. raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at RareCyte, Inc., from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at RareCyte, Inc.. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

RareCyte, Inc.

Location

2601 4th Avenue

Seattle, Washington, United States

About

Leaders across Research, Translational Medicine and the Clinic rely on RareCyte as a one-stop resource for Spatial Biology and Liquid Biopsy solutions. Headquartered in Seattle, WA, RareCyte is an innovative precision biology company that has developed technologies and end-to-end integrated platforms enabling advances in oncology, immuno-oncology, maternal-fetal health, and cell and gene therapy. Our highly multiplexed fluorescent imaging systems, reagents and contract services empower investigators to unlock spatial context for key biomarkers and develop therapeutics and companion diagnostics though rare cell analysis.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment RareCyte, Inc. raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

1 contact
Verified contactsDavid K., Director hiddenSee plans and pricing
Predictive Intelligence
Strategic

ML-powered predictions for RareCyte, Inc.'s next move

See what Strategic adds

RareCyte, Inc. raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.